+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Biosimilars Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Biosimilars Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083156
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilars Market grew from USD 49.91 billion in 2024 to USD 61.84 billion in 2025. It is expected to continue growing at a CAGR of 23.47%, reaching USD 176.90 billion by 2030.

The biosimilars sector has emerged as a critical driver of sustainable healthcare cost management and patient access to life-saving therapies. As biologic patents expire, manufacturers are leveraging advances in cell-culture technology, rigorous analytical methods and streamlined regulatory pathways to deliver high-quality alternatives that mirror the safety, efficacy and immunogenicity profiles of their reference products. This executive summary explores the key forces shaping the global biosimilars market, offering decision-makers an in-depth perspective on evolving policy frameworks, manufacturing innovations and competitive strategies. By synthesizing insights from regulatory shifts, trade policy impacts and granular segmentation analysis, this overview equips stakeholders-from payers and providers to developers and investors-with the strategic intelligence needed to navigate a landscape marked by rapid technological progress and complex market dynamics.

Transformative Shifts Redefining the Global Biosimilars Landscape

In recent years, the biosimilars landscape has undergone profound transformation, driven by breakthroughs in analytical characterization, regulatory harmonization and collaborative manufacturing models. Regulators across major markets have adopted abbreviated approval pathways, fostering convergence on requirements for comparative pharmacokinetics, pharmacodynamics and immunogenicity testing. Meanwhile, technological advancements-including continuous bioprocessing, single-use bioreactors and machine-learning-augmented quality control-have increased production efficiency and reduced time to market. Strategic alliances between contract development and manufacturing organizations and in-house capabilities have expanded global capacity, while digital platforms now enable end-to-end traceability and real-time supply-chain optimization. Together, these shifts have lowered barriers to entry for emerging players and intensified competition among established pharmaceutical leaders, ultimately accelerating patient access to affordable biologic therapies.

Assessing the Cumulative Impact of United States Tariffs in 2025

The introduction of new United States tariffs in 2025 has exerted substantial pressure on biosimilar import costs and supply-chain strategies. Manufacturers sourcing critical raw materials and active biologic ingredients from overseas have faced increased duty burdens, prompting a reevaluation of vendor networks and inventory buffers. As a result, some suppliers have accelerated investment in domestic manufacturing capacity and forged partnerships with contract manufacturing organizations headquartered within tariff-exempt jurisdictions. Payers and providers are concurrently grappling with marginal price inflation, leading to more stringent formulary negotiations and enhanced utilization management. However, the pressure to contain overall healthcare expenditures has also incentivized stakeholders to embrace biosimilars as high-value options, driving collaborative tendering models that help offset incremental tariff-related expenses.

Key Segmentation Insights Driving Market Trends

Detailed segmentation analysis reveals how varied product types, therapeutic applications and end-user settings shape market dynamics. Within erythropoietin biosimilars-further classified into darbepoetin alfa and epoetin alfa-demand is rising in dialysis centers and nephrology clinics driven by rising chronic kidney disorder prevalence. Fertility hormone biosimilars, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are gaining traction in reproductive health centers as patient affordability becomes paramount. In the granulocyte colony-stimulating factor segment, both filgrastim and pegfilgrastim alternatives are rapidly adopted in oncology departments to manage chemotherapy-induced neutropenia. Monoclonal antibody biosimilars for autoimmune diseases and oncology are diversifying treatment portfolios in specialized infusion clinics, while recombinant hormones such as human growth hormone and insulin are expanding home-care self-administration models. Application-wise, autoimmune disorder treatments for psoriasis and rheumatoid arthritis are establishing footholds alongside chronic disease therapies for diabetes and kidney disorders. Genetic disorder biosimilars for cystic fibrosis and hemophilia are at an early uptake stage in tertiary hospitals, and infectious disease portfolios addressing hepatitis and HIV/AIDS are driving demand in public health programs. Manufacturing type segmentation shows contract developers offering large-scale biologics manufacturing services in high-capacity facilities, while in-house production units focus on specialized small-batch capabilities. Route of administration insights highlight that single-use intramuscular vials, bolus injection intravenous formats and subcutaneous autoinjectors are each capturing unique market share based on convenience and patient adherence. End-user segmentation demonstrates that outpatient and specialized clinics, private and public hospitals, home-healthcare agencies and academic research centers are tailoring biosimilar adoption strategies to clinical workflow and budgetary constraints. Finally, therapeutic class analysis underscores that anticancer biosimilars, including HER2 and VEGF inhibitors, are commanding substantial market attention alongside autoimmune interferons, TNF inhibitors, long-acting and rapid-acting insulin analogs, and somatropin for growth hormone deficiency.

Critical Regional Insights Shaping Biosimilars Adoption

Regional dynamics continue to play a decisive role in biosimilars uptake and commercialization. In the Americas, progressive reimbursement policies and competitive tendering have positioned the United States as a leading adopter, while Canada’s provincial formulary negotiations emphasize value-based pricing. Latin American markets are at varied maturity stages, with established programs in Brazil and Argentina contrasting with emerging regulatory frameworks across Central America. In Europe, Middle East and Africa, robust local manufacturing ecosystems in the European Union are complemented by accelerated approvals under the European Medicines Agency’s guidelines, even as pricing disputes in the United Kingdom and federated negotiations within Gulf Cooperation Council states add complexity. Africa’s nascent biosimilar programs are catalyzed by public-private partnerships and WHO prequalification initiatives. Asia-Pacific markets are characterized by dual drivers: China and India leverage vast biomanufacturing capabilities to supply both domestic and export demand, while Japan and Australia blend cautious regulatory reforms with high-value reimbursement schemes. Southeast Asian nations are rapidly updating biosimilar guidelines, supported by regional harmonization via ASEAN, to enhance patient access and stimulate local production.

Competitive Landscape and Key Company Profiles

The competitive landscape is defined by a diverse array of global and regional players forging unique strategies to capture market share. Alvotech is securing partnerships to co-develop monoclonal antibody biosimilars while Amgen Inc. leverages its extensive biologics heritage to expand its portfolio across oncology and autoimmune categories. Apotex Inc. and Biocon Limited focus on cost-efficient insulin and growth hormone biosimilars, whereas BioFactura, Inc. and Biogen Inc. emphasize innovative CMO services and differentiated formulations. Boehringer Ingelheim International GmbH and Catalent, Inc. are scaling advanced manufacturing platforms to meet rising demand, and Celltrion Healthcare Co., Ltd. and Coherus BioSciences pursue aggressive global rollouts with competitive pricing. Dr. Reddy’s Laboratories Limited and Eden Biologics, Inc. concentrate on emerging markets, complemented by F. Hoffmann-La Roche AG’s reference biologic stewardship. Fresenius Kabi and Innovent Biologics, Inc. harness strategic alliances for recombinant hormone variants, while Intas Pharmaceuticals Ltd. and Kashiv BioSciences, LLC prioritize high-volume contract manufacturing agreements. Merck & Co., Inc. and NeuClone advance novel regulatory and clinical pathways, with Nippon Kayaku Co., Ltd. and Novartis AG leveraging local partnerships in Asia. Panacea Biotec Limited and Pfizer Inc. target immunogenicity-optimized formulations, Samsung Bioepis Co., Ltd. and Sanofi S.A. integrate digital patient support solutions, while Shanghai Henlius Biotech, Inc. and Teva Pharmaceutical Industries Ltd. pioneer biosimilar interchangeability programs. Thermo Fisher Scientific, Inc. supports the sector through cutting-edge analytical instrumentation and bioprocess consumables essential for comparability studies.

Actionable Recommendations for Industry Leadership and Growth

Industry leaders should prioritize several strategic initiatives to secure long-term biosimilar success. First, investing in flexible manufacturing architectures-combining single-use systems with continuous processing-will ensure rapid scale-up capabilities and resilience against supply-chain disruptions. Second, establishing early engagement with payers to design outcome-based contracting and shared-risk reimbursement models can accelerate market access and secure formulary placement. Third, strengthening analytical comparability programs through advanced multi-omics and digital twins will expedite regulatory approval and reinforce clinical confidence. Fourth, forming strategic alliances with regional partners in high-growth markets can mitigate tariff exposures and optimize distribution networks. Fifth, integrating patient-centric support platforms-including digital adherence tools and remote monitoring-will drive better clinical outcomes and differentiate biosimilar offerings. By executing these initiatives, organizations can align operational excellence with market intelligence to outpace competition and meet evolving stakeholder expectations.

Conclusion: Strategic Imperatives for Biosimilars Success

The biosimilars sector stands at a pivotal juncture wherein regulatory evolution, manufacturing innovation and competitive intensity converge to define future growth trajectories. Stakeholders who navigate tariff headwinds, embrace data-driven comparability and cultivate strategic partnerships across regions will be best positioned to deliver cost-effective biologic therapies at scale. As the market matures, success will hinge on a proactive approach to reimbursement negotiations, patient engagement and supply-chain agility. By synthesizing these strategic imperatives, decision-makers can capitalize on the biosimilars revolution to improve patient access, enhance healthcare sustainability and secure a competitive edge in an increasingly dynamic pharmaceutical ecosystem.

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Erythropoietin
    • Darbepoetin Alfa
    • Epoetin Alfa
  • Fertility Hormones
    • Follicle-Stimulating Hormone (FSH)
    • Luteinizing Hormone (LH)
  • Granulocyte Colony-Stimulating Factor (G-CSF)
    • Filgrastim
    • Pegfilgrastim
  • Monoclonal Antibodies
    • Autoimmune Diseases
    • Oncology
  • Recombinant Hormones
    • Human Growth Hormone
    • Insulin
  • Autoimmune Disorders
    • Psoriasis
    • Rheumatoid Arthritis
  • Chronic Diseases
    • Diabetes
    • Kidney Disorders
  • Genetic Disorders
    • Cystic Fibrosis
    • Hemophilia
  • Infectious Diseases
    • Hepatitis
    • HIV/AIDS
  • Oncology Disorders
    • Breast Cancer
    • Colorectal Cancer
  • Contract Manufacturing
    • Biologics Manufacturing Services
    • Specialized Manufacturing
  • In-House Manufacturing
    • Large-Scale Facilities
    • Small-Scale Facilities
  • Intramuscular
    • Single Use Vials
  • Intravenous
    • Bolus Injection
    • Continuous Infusion
  • Subcutaneous
    • Autoinjectors
    • Prefilled Syringes
  • Clinics
    • Outpatient Clinics
    • Specialized Clinics
  • Home Care Settings
    • Home-Healthcare Agencies
    • Self-Administration
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Centers
    • Academic Institutions
    • Private Research Facilities
  • Anticancer Biosimilars
    • HER2 Inhibitors
    • VEGF Inhibitors
  • Autoimmune Biosimilars
    • Interferon
    • TNF Inhibitors
  • Diabetes Biosimilars
    • Long Acting Insulins
    • Rapid Acting Insulins
  • Growth Hormone Deficiency
    • Somatropin

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biosimilars Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck & Co., Inc.
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilars Market, by Product Type
8.1. Introduction
8.2. Erythropoietin
8.2.1. Darbepoetin Alfa
8.2.2. Epoetin Alfa
8.3. Fertility Hormones
8.3.1. Follicle-Stimulating Hormone (FSH)
8.3.2. Luteinizing Hormone (LH)
8.4. Granulocyte Colony-Stimulating Factor (G-CSF)
8.4.1. Filgrastim
8.4.2. Pegfilgrastim
8.5. Monoclonal Antibodies
8.5.1. Autoimmune Diseases
8.5.2. Oncology
8.6. Recombinant Hormones
8.6.1. Human Growth Hormone
8.6.2. Insulin
9. Biosimilars Market, by Application
9.1. Introduction
9.2. Autoimmune Disorders
9.2.1. Psoriasis
9.2.2. Rheumatoid Arthritis
9.3. Chronic Diseases
9.3.1. Diabetes
9.3.2. Kidney Disorders
9.4. Genetic Disorders
9.4.1. Cystic Fibrosis
9.4.2. Hemophilia
9.5. Infectious Diseases
9.5.1. Hepatitis
9.5.2. HIV/AIDS
9.6. Oncology Disorders
9.6.1. Breast Cancer
9.6.2. Colorectal Cancer
10. Biosimilars Market, by Manufacturing Type
10.1. Introduction
10.2. Contract Manufacturing
10.2.1. Biologics Manufacturing Services
10.2.2. Specialized Manufacturing
10.3. In-House Manufacturing
10.3.1. Large-Scale Facilities
10.3.2. Small-Scale Facilities
11. Biosimilars Market, by Route of Administration
11.1. Introduction
11.2. Intramuscular
11.2.1. Single Use Vials
11.3. Intravenous
11.3.1. Bolus Injection
11.3.2. Continuous Infusion
11.4. Subcutaneous
11.4.1. Autoinjectors
11.4.2. Prefilled Syringes
12. Biosimilars Market, by End User
12.1. Introduction
12.2. Clinics
12.2.1. Outpatient Clinics
12.2.2. Specialized Clinics
12.3. Home Care Settings
12.3.1. Home-Healthcare Agencies
12.3.2. Self-Administration
12.4. Hospitals
12.4.1. Private Hospitals
12.4.2. Public Hospitals
12.5. Research Centers
12.5.1. Academic Institutions
12.5.2. Private Research Facilities
13. Biosimilars Market, by Therapeutic Class
13.1. Introduction
13.2. Anticancer Biosimilars
13.2.1. HER2 Inhibitors
13.2.2. VEGF Inhibitors
13.3. Autoimmune Biosimilars
13.3.1. Interferon
13.3.2. TNF Inhibitors
13.4. Diabetes Biosimilars
13.4.1. Long Acting Insulins
13.4.2. Rapid Acting Insulins
13.5. Growth Hormone Deficiency
13.5.1. Somatropin
14. Americas Biosimilars Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Biosimilars Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Biosimilars Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Alvotech
17.3.2. Amgen Inc.
17.3.3. Apotex Inc.
17.3.4. Biocon Limited
17.3.5. BioFactura, Inc.
17.3.6. Biogen Inc.
17.3.7. Boehringer Ingelheim International GmbH.
17.3.8. Catalent, Inc
17.3.9. Celltrion Healthcare Co.,Ltd.
17.3.10. Coherus BioSciences
17.3.11. Dr. Reddy's Laboratories Limited
17.3.12. Eden Biologics, Inc.
17.3.13. F. Hoffmann-La Roche AG
17.3.14. Fresenius Kabi
17.3.15. Innovent Biologics, Inc.
17.3.16. Intas Pharmaceuticals Ltd.
17.3.17. Kashiv BioSciences, LLC.
17.3.18. Merck & Co., Inc.
17.3.19. NeuClone
17.3.20. Nippon Kayaku Co., Ltd.
17.3.21. Novartis AG
17.3.22. Panacea Biotec Limited
17.3.23. Pfizer Inc.
17.3.24. Samsung Bioepis Co., Ltd.
17.3.25. Sanofi S.A.
17.3.26. Shanghai Henlius Biotech, Inc.
17.3.27. Teva Pharmaceutical Industries Ltd.
17.3.28. Thermo Fisher Scientific, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIOSIMILARS MARKET MULTI-CURRENCY
FIGURE 2. BIOSIMILARS MARKET MULTI-LANGUAGE
FIGURE 3. BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLICLE-STIMULATING HORMONE (FSH), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY LUTEINIZING HORMONE (LH), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY KIDNEY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY SPECIALIZED MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY LARGE-SCALE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY SMALL-SCALE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOSIMILARS MARKET SIZE, BY SINGLE USE VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILARS MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOINJECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOSIMILARS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOSIMILARS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOSIMILARS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOSIMILARS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIOSIMILARS MARKET SIZE, BY HOME-HEALTHCARE AGENCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BIOSIMILARS MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BIOSIMILARS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BIOSIMILARS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BIOSIMILARS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BIOSIMILARS MARKET SIZE, BY PRIVATE RESEARCH FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BIOSIMILARS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL BIOSIMILARS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL BIOSIMILARS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL BIOSIMILARS MARKET SIZE, BY LONG ACTING INSULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL BIOSIMILARS MARKET SIZE, BY RAPID ACTING INSULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL BIOSIMILARS MARKET SIZE, BY SOMATROPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. AMERICAS BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 106. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 165. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 178. BRAZIL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 179. BRAZIL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 190. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. CANADA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 192. CANADA BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 193. CANADA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 194. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 195. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 196. CANADA BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. CANADA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 198. CANADA BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 199. CANADA BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 200. CANADA BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 201. CANADA BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 203. CANADA BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 204. CANADA BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 205. CANADA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. CANADA BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 207. CANADA BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 208. CANADA BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 209. CANADA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. CANADA BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 211. CANADA BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 212. CANADA BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 213. CANADA BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 214. CANADA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 215. CANADA BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 216. CANADA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 217. CANADA BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 218. CANADA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 219. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. MEXICO BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 221. MEXICO BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 222. MEXICO BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 223. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 224. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 225. MEXICO BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. MEXICO BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. MEXICO BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 228. MEXICO BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 229. MEXICO BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 230. MEXICO BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 231. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 232. MEXICO BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 233. MEXICO BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 234. MEXICO BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. MEXICO BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 236. MEXICO BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 237. MEXICO BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 238. MEXICO BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. MEXICO BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 240. MEXICO BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 241. MEXICO BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. MEXICO BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 243. MEXICO BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 244. MEXICO BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 245. MEXICO BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 246. MEXICO BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 247. MEXICO BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 248. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 250. UNITED STATES BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 251. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 252. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 253. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 254. UNITED STATES BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 256. UNITED STATES BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 257. UNITED STATES BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. UNITED STATES BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 259. UNITED STATES BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 260. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 261. UNITED STATES BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 262. UNITED STATES BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 263. UNITED STATES BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 265. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 266. UNITED STATES BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 267. UNITED STATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. UNITED STATES BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 269. UNITED STATES BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 270. UNITED STATES BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. UNITED STATES BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 272. UNITED STATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 273. UNITED STATES BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 274. UNITED STATES BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 275. UNITED STATES BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 276. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 277. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 280. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 282. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 284. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 286. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 287. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 288. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 289. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 290. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 311. AUSTRALIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 312. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 313. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 314. AUSTRALIA BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 315. AUSTRALIA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. AUSTRALIA BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 317. AUSTRALIA BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 318. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 319. AUSTRALIA BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 320. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 321. AUSTRALIA BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 322. AUSTRALIA BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 323. AUSTRALIA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 325. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 326. AUSTRALIA BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, 2018-2030 (USD MILLION)
TABLE 327. AUSTRALIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. AUSTRALIA BIOSIMILARS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 329. AUSTRALIA BIOSIMILARS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA BIOSIMILARS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA BIOSIMILARS MARKET SIZE, BY ANTICANCER BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA BIOSIMILARS MARKET SIZE, BY DIABETES BIOSIMILARS, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, 2018-2030 (USD MILLION)
TABLE 337. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. CHINA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, 2018-2030 (USD MILLION)
TABLE 339. CHINA BIOSIMILARS MARKET SIZE, BY FERTILITY HORMONES, 2018-2030 (USD MILLION)
TABLE 340. CHINA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF), 2018-2030 (USD MILLION)
TABLE 341. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 342. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 343. CHINA BIOSIMILARS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 344. CHINA BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2030 (USD MILLION)
TABLE 345. CHINA BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, 2018-2030 (USD MILLION)
TABLE 346. CHINA BIOSIMILARS MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 347. CHINA BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 348. CHINA BIOSIMILARS MARKET SIZE, BY ONCOLOGY DISORDERS, 2018-2030 (USD MILLION)
TABLE 349. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING TYPE, 2018-2030 (USD MILLION)
TABLE 350. CHINA BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 351. CHINA BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 352. CHINA BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 353. CHINA BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, 2018-20

Companies Mentioned

  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck & Co., Inc.
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030 - Product Image

Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Biologics & Biosimilars CXO Services Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global, United States Global, United States
From
Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Biosimilars Market - Products, Applications and Regulations - Product Image

Biosimilars Market - Products, Applications and Regulations

  • Report
  • 227 Pages
  • Global
From
Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players - Product Image

Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players

  • Report
  • 319 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.